Golden Recursion Inc. logoGolden Recursion Inc. logo
Advanced Search


Lenire is an evidence-based tinnitus treatment from Neuromod, based on the science of neuromodulation.

Lenire is an evidence-based tinnitus treatment developed and released in the UK by Neuromod in 2015. It is a non-invasive at-home medical device treatment method for chronic and persistent tinnitus (ringing in the ears). A clinician must prescribe Lenire, and treatment requires monitoring over a three-month time period as adjustments may be needed to optimize device effectiveness. A standard course of Lenire treatment lasts for 30 minutes and is used daily.

Case Study

A clinical trial of Lenire was conducted at the St James’s Hospital in Dublin and the Tinnituszentrum of the University Regensburg, Germany, from 2016-2019 and had 326 participants. The study results showed that approximately 86% of treatment-compliant patients reported tinnitus symptom improvement over a 12-week period, and approximately 80% of treatment-compliant patients reported improvement over a 12-month time period.


October 21, 2020
Neuromod has raised €10.5m in what it describes as an oversubscribed Series B financing.

"We are delighted to announce the successful completion of Series B financing, which will ramp up manufacturing of our Lenire tinnitus treatment device to meet demand across Europe," said founding CEO Ross O'Neill."

October 8, 2020
Neuromod publishes results of large-scale tinnitus clinical trial in peer-reviewed top-tier scientific journal.

"Neuromod Devices Limited (“Neuromod”), the Irish medical device company specializing in the treatment of chronic tinnitus, commonly described as ‘ringing in the ears’, has published the results of the Company’s TENT A1 (Treatment Evaluation of Neuromodulation for Tinnitus) clinical trial in this week’s edition of Science Translational Medicine"

Further Resources



Golden logo
By using this site, you agree to our Terms & Conditions.